NASDAQ:TVRD Tvardi Therapeutics (TVRD) Stock Price, News & Analysis $24.00 +0.21 (+0.88%) As of 08/15/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Tvardi Therapeutics Stock (NASDAQ:TVRD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tvardi Therapeutics alerts:Sign Up Key Stats Today's Range$23.79▼$24.6250-Day Range$21.45▼$29.8352-Week Range$8.13▼$34.31Volume12,588 shsAverage Volume26,996 shsMarket Capitalization$224.64 millionP/E RatioN/ADividend YieldN/APrice Target$64.25Consensus RatingBuy Company Overview Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut. Read More Receive TVRD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TVRD Stock News HeadlinesTvardi Therapeutics expects cash to fund operations into Q4 2026August 15 at 2:48 AM | msn.comTvardi Therapeutics reports Q2 EPS ($1.00) vs ($2.71) last yearAugust 15 at 2:48 AM | msn.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 17 at 2:00 AM | Brownstone Research (Ad)Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business UpdateAugust 14 at 6:40 PM | finance.yahoo.comRaymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform RecommendationJuly 15, 2025 | msn.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | finance.yahoo.comTvardi Therapeutics to Participate in the BTIG Virtual Biotechnology ConferenceJuly 15, 2025 | businesswire.comCantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight RecommendationJuly 12, 2025 | msn.comSee More Headlines TVRD Stock Analysis - Frequently Asked Questions How have TVRD shares performed this year? Tvardi Therapeutics' stock was trading at $29.09 at the start of the year. Since then, TVRD shares have decreased by 17.5% and is now trading at $24.00. How were Tvardi Therapeutics' earnings last quarter? Tvardi Therapeutics, Inc. (NASDAQ:TVRD) posted its earnings results on Thursday, August, 14th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.49. Tvardi Therapeutics had a negative net margin of 595.39% and a negative trailing twelve-month return on equity of 710.04%. Who are Tvardi Therapeutics' major shareholders? Tvardi Therapeutics' top institutional investors include Slate Path Capital LP (7.52%), 683 Capital Management LLC (1.88%), Geode Capital Management LLC (1.20%) and Marshall Wace LLP (0.27%). How do I buy shares of Tvardi Therapeutics? Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/14/2025Today8/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TVRD Previous SymbolNASDAQ:TVRD CIK1346830 WebN/A Phone(203) 406-3700Fax203-567-1510Employees80Year FoundedN/APrice Target and Rating Average Price Target for Tvardi Therapeutics$64.25 High Price Target$78.00 Low Price Target$52.00 Potential Upside/Downside+167.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$70.87 million Net Margins-595.39% Pretax Margin-600.65% Return on Equity-710.04% Return on Assets-37.18% Debt Debt-to-Equity RatioN/A Current Ratio32.48 Quick Ratio31.73 Sales & Book Value Annual Sales$7.14 million Price / Sales31.46 Cash FlowN/A Price / Cash FlowN/A Book Value($3.02) per share Price / Book-7.95Miscellaneous Outstanding Shares9,360,000Free Float9,071,000Market Cap$224.64 million OptionableN/A Beta0.21 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:TVRD) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.